mouth sores – Oral Cancer News

Non-Irritating Foods to Eat When You Have Mouth Sores

Author: Suzanne Dixon, MPH, RD Source: www.verywellhealth.com What You Can Do About Oral Mucositis The loss of appetite is common when undergoing cancer treatment, particularly if you get a common side effect called oral mucositis which causes mouth sores. To ensure proper nutrition to help you heal, you need to find non-irritating foods that you can eat even if you have mouth sores. This article explains why mouth sores occur in people undergoing cancer treatment. It also lists the types of food you can and cannot eat—as well as the way to eat—to better cope with treatment-induced oral mucositis. How Cancer Treatment Causes Mouth Sores Over 40% of people undergoing certain cancer treatments will develop oral mucositis. It is most commonly associated with chemotherapy but can also occur with radiation therapy to the head or neck. Oral mucositis is an especially common occurrence when exposed to the chemotherapy drugs 5-fluorouracil (5-FU) or Evomela (melphalan). Other chemotherapy drugs can do the same. Treatment-induced oral mucositis is the result of the following processes: Whenever cells are damaged by chemotherapy or radiation, they release unstable atoms called free radicals. This, in turn, triggers the release of inflammatory chemicals called cytokines and metalloproteinase that break down a structural protein called collagen, causing tissues to thin and form ulcers. When this occurs in the mouth, natural bacteria quickly colonize the sores, causing infection, inflammation, and pain. The sores can often be extremely painful, making it difficult to eat, talk, and swallow. The sores may even [...]

OCF News Team - B2022-08-12T06:28:46-07:00August, 2022|Oral Cancer News|

Public lacks awareness of head and neck cancer

Source: www.alberniportal.ca Author: Leatitia Michael A survey reveals that the general public, including those who smoke, do not know very much about oral, head, and neck cancer (OHNC). There were nearly 40,000 new cases of oral, head and neck cancer diagnosed last year in the USA, of which 85 per cent could be linked to tobacco use and heavy alcohol consumption. Yet, according to a survey from the Medical University of South Carolina, the public remains largely unaware of the risks. In the study, over 1,000 members of the public were telephoned and 62 per cent said they were not knowledgeable about OHNC. Among smokers, the lack of awareness ran at 58 per cent. Under half of non-smokers and smokers knew that smoking was a risk factor. Hoarseness was correctly identified as a symptom by only one per cent of smokers and two per cent overall. But 17 per cent of the sample incorrectly named headache as a symptom. People can spot the signs and symptoms of OHNC themselves, but 94 per cent had not been told to look for problems like mouth sores that do not heal. And only 26 per cent had been check for this by a doctor. Clearly there is some way to go in raising awareness among the public of OHNC.

Oral Cancer Foundation News Team - A2013-05-14T08:35:21-07:00May, 2013|Oral Cancer News|

Oral spray reduces mouth sores

Source: patient.cancerconsultants.com Author: staff Among patients treated with radiation therapy for head and neck cancer, mouth sores (oral mucositis) were reduced by use of an oral spray containing epidermal growth factor (EGF). These results were published in Cancer. Mouth sores are one of the most common and serious complications of radiation therapy for head and neck cancer. Mouth sores are painful, interfere with eating and drinking, and can also lead to infection. If they become severe enough they may require a reduction or delay in cancer treatment. Epidermal growth factor (EGF) is a protein that plays several important roles in the body, including wound healing and tissue growth. To evaluate the use of an EGF-containing oral spray for the treatment of mouth sores, researchers in Korea conducted a Phase II clinical trial among 113 patients with head and neck cancer. The most common sites of cancer among the study participants were the nasopharynx, oropharynx, and oral cavity. All of the patients were treated with radiation therapy with or without chemotherapy. In addition, patients were assigned to receive one of three doses of the EGF oral spray or a placebo. The spray was used twice a day through week five of radiation therapy. Patients were considered to have responded to the EGF spray or placebo if they had no mucositis or only mild mucositis at weeks 4 and 5 of radiation therapy. Response rate among patients in the placebo group was 37%. Response rates among patients in the EGF spray groups [...]

Oral Cancer Foundation News Team - A2009-07-22T05:23:02-07:00July, 2009|Oral Cancer News|